Vident Advisory
TLX icon

Vident Advisory’s Telix Pharmaceuticals TLX Stock Holding History

Vident Advisory’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$138K Sell
11,955
-4,698
-28% -$47.8K ﹤0.01% 1865
2026
Q1 		$159K Sell
16,653
-10,596
-39% -$80.7K ﹤0.01% 1750
2025
Q4 		$204K Buy
+27,249
New +$262K ﹤0.01% 1548

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return
Private Advisor Group
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Integrated Wealth Concepts
Integrated Wealth Concepts Waltham, Massachusetts $15.3B AUM 25.33% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Vident Advisory's TLX Position: Q2 2026 in Review

Vident Advisory reduced its Telix Pharmaceuticals (TLX) stake by 28% in Q2 2026, selling an estimated $47.8K and leaving 11,955 shares worth $138K. The position accounts for ﹤0.01% of the portfolio, ranked #1865.

Vident Advisory first reported a position in TLX in Q4 2025 and has held it in 3 quarters since. The position peaked at $204K in Q4 2025. 61 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • Vident Advisory held 11,955 shares of Telix Pharmaceuticals worth $138K as of Q2 2026.
  • Vident Advisory sold 4,698 Telix Pharmaceuticals shares in Q2 2026, an estimated $47.8K.
  • Telix Pharmaceuticals made up ﹤0.01% of Vident Advisory's portfolio in Q2 2026, its #1865 holding.
  • Vident Advisory first reported a position in Telix Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Vident Advisory's Telix Pharmaceuticals position peaked at $204K in Q4 2025.
  • 61 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.